Nonlesional diffusely abnormal appearing white matter in clinically isolated syndrome: Prevalence, association with clinical and MRI features, and risk for conversion to multiple sclerosis.
clinically isolated syndrome
diffusely abnormal white matter
magnetic resonance imaging
multiple sclerosis
Journal
Journal of neuroimaging : official journal of the American Society of Neuroimaging
ISSN: 1552-6569
Titre abrégé: J Neuroimaging
Pays: United States
ID NLM: 9102705
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
26
05
2021
received:
19
04
2021
accepted:
28
05
2021
pubmed:
16
6
2021
medline:
27
10
2021
entrez:
15
6
2021
Statut:
ppublish
Résumé
While diffusely abnormal white matter (DAWM) is a nonlesional MRI abnormality identified in ∼25% of patients with multiple sclerosis (MS), it has yet to be investigated in patients at an earlier disease stage, namely clinically isolated syndrome (CIS). The goals of this study were to (1) determine the prevalence of DAWM in patients with a CIS suggestive of MS, (2) evaluate the association between DAWM and demographic, clinical, and MRI features, and (3) evaluate the prognostic significance of DAWM on conversion from CIS to MS. One hundred and forty-two CIS participants were categorized into DAWM and non-DAWM groups at baseline and followed for up to 24 months or until MS diagnosis. The primary outcome was conversion to MS (2005 McDonald criteria) within 6 months. DAWM was present in 27.5% of participants, and was positively associated with brainstem symptom onset, receiving corticosteroids, dissemination in space, and T DAWM is present in a similar proportion of patients with CIS and clinically definite MS, and it is associated with increased risk of conversion to MS over 6 months.
Sections du résumé
BACKGROUND AND PURPOSE
While diffusely abnormal white matter (DAWM) is a nonlesional MRI abnormality identified in ∼25% of patients with multiple sclerosis (MS), it has yet to be investigated in patients at an earlier disease stage, namely clinically isolated syndrome (CIS). The goals of this study were to (1) determine the prevalence of DAWM in patients with a CIS suggestive of MS, (2) evaluate the association between DAWM and demographic, clinical, and MRI features, and (3) evaluate the prognostic significance of DAWM on conversion from CIS to MS.
METHODS
One hundred and forty-two CIS participants were categorized into DAWM and non-DAWM groups at baseline and followed for up to 24 months or until MS diagnosis. The primary outcome was conversion to MS (2005 McDonald criteria) within 6 months.
RESULTS
DAWM was present in 27.5% of participants, and was positively associated with brainstem symptom onset, receiving corticosteroids, dissemination in space, and T
CONCLUSIONS
DAWM is present in a similar proportion of patients with CIS and clinically definite MS, and it is associated with increased risk of conversion to MS over 6 months.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
981-994Informations de copyright
© 2021 American Society of Neuroimaging.
Références
Louapre C, Bodini B, Lubetzki C, Freeman L, Stankoff B. Imaging markers of multiple sclerosis prognosis. Curr Opin Neurol 2017;30:231-6.
De Stefano N, Airas L, Grigoriadis N, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014;28:147-56.
Vertinsky AT, Li DKB, Vavasour IM, et al. Diffusely abnormal white matter, T2 burden of disease, and brain volume in relapsing-remitting multiple sclerosis. J Neuroimaging 2019;29:151-9.
Zhao G, Li D, Cheng Y. MRI dirty-appearing white matter in MS (abstract). Neurology 2000;54(Suppl 3):A121.
Chen SC-Y, Chung H-W, Liou M. Measurement of volumetric lesion load in multiple sclerosis: moving from normal- to dirty-appearing white matter. AJNR Am J Neuroradiol 2003;24:1929-30.
Ge Y, Grossman RI, Babb JS, He J, Mannon LJ. Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol 2003;24:1935-40.
Vrenken H, Seewann A, Knol DL, Polman CH, Barkhof F, Geurts JJG. Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. AJNR Am J Neuroradiol 2010;31:541-8.
Seewann A, Vrenken H, van der Valk P, et al. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Arch Neurol 2009;66:601-9.
Laule C, Vavasour IM, Leung E, et al. Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology: Mult Scler 2010;17:144-50.
Laule C, Pavlova V, Leung E, et al. Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration. J Neuropathol Exp Neurol 2013;72:42-52.
Moore GRW, Laule C, MacKay A, et al. Dirty-appearing white matter in multiple sclerosis (abstract). J Neurol 2008;255(11):1802.
West J, Aalto A, Tisell A, et al. Normal appearing and diffusely abnormal white matter in patients with multiple sclerosis assessed with quantitative MR. PLoS One 2014;9:e95161.
Dadar M, Narayanan S, Arnold DL, Collins DL, Maranzano J. Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis. Mult Scler 2021;27:208-19.
Maranzano J, Dadar M, Arnold DL, Collins DL, Narayanan S. Automated separation of diffusely abnormal white matter from focal white matter lesions on MRI in multiple sclerosis. Neuroimage 2019;213:116690.
Vavasour IM, Li D, Traboulsee A, et al. Using MRI to explore myelin in normal appearing and diffusely abnormal white matter in multiple sclerosis (abstract). Mult Scler 2019;25(S1):P202.
Metz LM, Li DKB, Traboulsee AL, et al. Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med 2017;376:2122-33.
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005;58:840-6.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
Pluim JPW, Maintz JBA, Viergever MA. Mutual-information-based registration of medical images: a survey. IEEE Trans Med Imaging 2003;22:986-1004.
McAusland J, Tam RC, Wong E, Riddehough A, Li DKB. Optimizing the use of radiologist seed points for improved multiple sclerosis lesion segmentation. IEEE Trans Biomed Eng 2010;57:2689-98.
Jones C, Li DK, Zhao G, Paty DW, Study Group PRISMS. Atrophy measurements in multiple sclerosis (abstract). Proceedings of the 9th International Society for Magnetic Resonance in Medicine Scientific Meeting & Exhibition. 2001:1414.
Polman C, Kappos L, Freedman MS, et al. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurol 2008;255:480-7.
Tintoré M, Rovira A, Rio J, et al. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 2005;57:210-5.
Sombekke MH, Wattjes MP, Balk LJ, et al. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology 2013;80:69-75.
Gaetani L, Fanelli F, Riccucci I, et al. High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. J Neurol Sci 2017;379:236-40.
Alroughani R, Al Hashel J, Lamdhade S, Ahmed SF. Predictors of conversion to multiple sclerosis in patients with clinical isolated syndrome using the 2010 revised McDonald criteria. ISRN Neurol 2012;2012:792192.
Moraal B, Pohl C, Uitdehaag BMJ, et al. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT Study. Arch Neurol 2009;66:1345-52.
Shaheen HA, Sayed SS, Daker LI, Taha MA. Early predictors of conversion in patients with clinically isolated syndrome: a preliminary Egyptian study. Egypt J Neurol Psychiatry Neurosurg 2018;54:21-6.
Dobson R, Ramagopalan S, Giovannoni G. The effect of gender in clinically isolated syndrome (CIS): a meta-analysis. Mult Scler 2012;18:600-4.
Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 1993;116:135-46.
Dworkin JD, Linn KA, Oguz I, et al. An automated statistical technique for counting distinct multiple sclerosis lesions. Am J Neuroradiol 2018;39:626-33.
Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler 2015;21:1013-24.
Dalla Costa G, Passerini G, Messina MJ, et al. Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes. J Neuroimmunol 2015;289:62-7.
Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:141-7.
Iannucci G, Tortorella C, Rovaris M, Sormani MP, Comi G, Filippi M. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. Am J Neuroradiol 2000;21:1034-8.
Raz E, Cercignani M, Sbardella E, et al. Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. Radiology 2009;254:227-34.
Kalincik T, Vaneckova M, Tyblova M, et al. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS One 2012;7:e50101.
Pérez-Miralles F, Sastre-Garriga J, Tintoré M, et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler 2013;19:1878-86.
Popescu V, Schoonheim MM, Versteeg A, et al. Grey matter atrophy in multiple sclerosis: clinical interpretation depends on choice of analysis method. PLoS One 2016;11:e0143942.
Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain J Neurol 1997;120:2059-69.
Tintoré M, Rovira A, Martínez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702-6.
Korteweg T, Tintore M, Uitdehaag BMJ, et al. A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. Eur Radiol 2009;19:2244-8.
Nielsen JM, Pohl C, Polman CH, et al. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurol 2009;9:19-28.
Ro L-S, Yang C-C, Lyu R-K, et al. A prospective, observational study on conversion of clinically isolated syndrome to multiple sclerosis during 4-year period (MS NEO study) in Taiwan. PLoS One 2019;14:e0202453.
Tintoré M, Rovira A, Río J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-72.
Brex PA, O'Riordan JI, Miszkiel KA, et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999;53:1184-90.
Çinar BP, Özakbaş S. Prediction of conversion from clinically isolated syndrome to multiple sclerosis according to baseline characteristics: a prospective study. Arch Neuropsychiatry 2018;55:15-21.
Nielen MM, den Boer JA, Smid HGOM. Patients with obsessive-compulsive disorder are impaired in associative learning based on external feedback. Psychol Med 2009;39:1519-26.
Pestalozza IF, Pozzilli C, Di Legge S, et al. Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. Mult Scler 2005;11:390-4.
D'Alessandro R, Vignatelli L, Lugaresi A, et al. Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. J Neurol 2013;260:1583-93.
Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-64.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162-73.
Lee D-H, Peschke M, Utz KS, Linker RA. Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing-remitting multiple sclerosis. Eur J Neurol 2019;26:540-5.